Nkarta Reports Q4 Results and Reaffirms Guidance 
<p><a href='https://financialmodelingprep.com/financial-summary/NKTX'>Nkarta, Inc. (Nasdaq: NKTX)</a>, a biopharmaceutical company focused on developing engineered natural killer (NK) cell therapies for cancer treatment, reported its Q4 earnings, reaffirmed its prior guidance that updated results from NKX101’s Phase 1 trial will be reported in H1/23. </p>
<p>Analysts Oppenheimer believe the readout will be an important indicator of sentiment for the cancer cell therapy field. According to the analysts, NKX101 is one of the first cell therapies to show clear activity in AML. How the stock reacts to the H1/23 update could very well be a signal of things to come from a market perspective, especially if the data are good but not flawless. The analysts continue to believe the program must show promise at treating patients with high-burden diseases.</p>

Nasdaq:, NKTX